MARKET

BCAX

BCAX

Bicara Therapeutics
NASDAQ
9.12
-0.26
-2.77%
After Hours: 9.01 -0.11 -1.21% 19:30 11/19 EST
OPEN
9.40
PREV CLOSE
9.38
HIGH
9.55
LOW
9.05
VOLUME
844.69K
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
7.87
MARKET CAP
605.45M
P/E (TTM)
-2.6345
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCAX last week (1109-1113)?
Weekly Report · 3d ago
Bicara Therapeutics Earnings Call Highlights Trial Progress
TipRanks · 5d ago
Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/11 12:51
Bicara Therapeutics Price Target Cut to $36.00/Share From $42.00 by HC Wainwright & Co.
Dow Jones · 11/11 12:51
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36
Benzinga · 11/11 12:40
Bicara Therapeutics price target lowered to $36 from $42 at H.C. Wainwright
TipRanks · 11/11 11:56
Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 11/10 17:11
Bicara Therapeutics Price Target Cut to $30.00/Share From $41.00 by Morgan Stanley
Dow Jones · 11/10 17:11
More
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

Webull offers Bicara Therapeutics Inc. stock information, including NASDAQ: BCAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAX stock methods without spending real money on the virtual paper trading platform.